TESARO (TSRO) Tops Q1 EPS by 39c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
TESARO Announces First-Quarter 2016 Operating Results
May 5, 2016 4:09 PM EDTU.S. launch of VARUBI® underway; New Drug Application (NDA) for IV formulation of rolapitant submittedNiraparib Phase 3 NOVA results anticipated in Q2 2016 are positioned to be the first data from a randomized, prospective Phase 3 trial of a PARP inhibitorNDA and MAA submissions for niraparib planned for 2H 2016Collaboration with Janssen now underway to develop niraparib for patients with prostate cancerPhase 1 trial of TSR-042 initiated and Investigational New Drug (IND) application for TSR-022 (anti-TIM-3 antibody) submitted to FDACash and cash equivalents totaled... More
